148 related articles for article (PubMed ID: 27793881)
1. Therapeutic Innovations for Targeting Hepatoblastoma.
Garnier A; Ilmer M; Kappler R; Berger M
Anticancer Res; 2016 Nov; 36(11):5577-5592. PubMed ID: 27793881
[TBL] [Abstract][Full Text] [Related]
2. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Neurokinin-1 Receptor Compromises Canonical Wnt Signaling in Hepatoblastoma.
Ilmer M; Garnier A; Vykoukal J; Alt E; von Schweinitz D; Kappler R; Berger M
Mol Cancer Ther; 2015 Dec; 14(12):2712-21. PubMed ID: 26516161
[TBL] [Abstract][Full Text] [Related]
4. Targeting the neurokinin-1 receptor inhibits growth of human colon cancer cells.
Garnier A; Vykoukal J; Hubertus J; Alt E; von Schweinitz D; Kappler R; Berger M; Ilmer M
Int J Oncol; 2015 Jul; 47(1):151-60. PubMed ID: 25998227
[TBL] [Abstract][Full Text] [Related]
5. Activation of phosphatidylinositol-3'-kinase/AKT signaling is essential in hepatoblastoma survival.
Hartmann W; Küchler J; Koch A; Friedrichs N; Waha A; Endl E; Czerwitzki J; Metzger D; Steiner S; Wurst P; Leuschner I; von Schweinitz D; Buettner R; Pietsch T
Clin Cancer Res; 2009 Jul; 15(14):4538-45. PubMed ID: 19584164
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Innovations for Targeting Childhood Neuroblastoma: Implications of the Neurokinin-1 Receptor System.
Berger M; VON Schweinitz D
Anticancer Res; 2017 Nov; 37(11):5911-5918. PubMed ID: 29061769
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway.
Maira SM; Furet P; Stauffer F
Future Med Chem; 2009 Apr; 1(1):137-55. PubMed ID: 21426073
[TBL] [Abstract][Full Text] [Related]
8. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
Zhou Q; Lui VW; Yeo W
Future Oncol; 2011 Oct; 7(10):1149-67. PubMed ID: 21992728
[TBL] [Abstract][Full Text] [Related]
9. Activation of Wnt and Myc signaling in hepatoblastoma.
Cairo S; Armengol C; Buendia MA
Front Biosci (Elite Ed); 2012 Jan; 4(1):480-6. PubMed ID: 22201888
[TBL] [Abstract][Full Text] [Related]
10. beta-Catenin and met deregulation in childhood Hepatoblastomas.
Ranganathan S; Tan X; Monga SP
Pediatr Dev Pathol; 2005; 8(4):435-47. PubMed ID: 16211454
[TBL] [Abstract][Full Text] [Related]
11. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
Pang RW; Poon RT
Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
[TBL] [Abstract][Full Text] [Related]
12. Targeting of cell metabolism in human acute myeloid leukemia--more than targeting of isocitrate dehydrogenase mutations and PI3K/AKT/mTOR signaling?
Hauge M; Bruserud Ø; Hatfield KJ
Eur J Haematol; 2016 Mar; 96(3):211-21. PubMed ID: 26465810
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.
McCubrey JA; Steelman LS; Kempf CR; Chappell WH; Abrams SL; Stivala F; Malaponte G; Nicoletti F; Libra M; Bäsecke J; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Cocco L; Martelli AM
J Cell Physiol; 2011 Nov; 226(11):2762-81. PubMed ID: 21302297
[TBL] [Abstract][Full Text] [Related]
14. Discovery of benzenesulfonamide derivatives as potent PI3K/mTOR dual inhibitors with in vivo efficacies against hepatocellular carcinoma.
Chen Y; Zhang L; Yang C; Han J; Wang C; Zheng C; Zhou Y; Lv J; Song Y; Zhu J
Bioorg Med Chem; 2016 Mar; 24(5):957-66. PubMed ID: 26819001
[TBL] [Abstract][Full Text] [Related]
15. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
Zhang DM; Liu JS; Deng LJ; Chen MF; Yiu A; Cao HH; Tian HY; Fung KP; Kurihara H; Pan JX; Ye WC
Carcinogenesis; 2013 Jun; 34(6):1331-42. PubMed ID: 23393227
[TBL] [Abstract][Full Text] [Related]
16. Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.
Blachly JS; Baiocchi RA
Br J Haematol; 2014 Oct; 167(1):19-32. PubMed ID: 25100567
[TBL] [Abstract][Full Text] [Related]
17. Targeting autophagy to overcome drug resistance in cancer therapy.
Kumar A; Singh UK; Chaudhary A
Future Med Chem; 2015 Aug; 7(12):1535-42. PubMed ID: 26334206
[TBL] [Abstract][Full Text] [Related]
18. Drug resistance in hepatoblastoma.
Warmann SW; Fuchs J
Curr Pharm Biotechnol; 2007 Apr; 8(2):93-7. PubMed ID: 17430157
[TBL] [Abstract][Full Text] [Related]
19. Current and future management strategies for relapsed or progressive hepatoblastoma.
Venkatramani R; Furman WL; Fuchs J; Warmann SW; Malogolowkin MH
Paediatr Drugs; 2012 Aug; 14(4):221-32. PubMed ID: 22702740
[TBL] [Abstract][Full Text] [Related]
20. Elevated expression of Wnt antagonists is a common event in hepatoblastomas.
Koch A; Waha A; Hartmann W; Hrychyk A; Schüller U; Waha A; Wharton KA; Fuchs SY; von Schweinitz D; Pietsch T
Clin Cancer Res; 2005 Jun; 11(12):4295-304. PubMed ID: 15958610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
